血管加压素及血管加压素V1a型受体激动剂司来吉肽在感染性休克中的作用
The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock.
作者信息
Saad Antonio F, Maybauer Marc O
机构信息
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The University of Texas Medical Branch, Galveston, TX, USA; Division of Maternal Fetal Medicine, Department of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA.
Department of Anaesthesia, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; Critical Care Research Group, The Prince Charles Hospital and The University of Queensland, Brisbane, Qld, Australia; Department of Anaesthesiology and Intensive Care Medicine, Philipps University, Marburg, Germany.
出版信息
J Crit Care. 2017 Aug;40:41-45. doi: 10.1016/j.jcrc.2017.03.008. Epub 2017 Mar 15.
Septic shock remains one of the major causes of morbidity and mortality in the critically ill. Despite early goal therapy and administration of cathecholaminergic agents, up to 30% of patients succumb to the disease. In this manuscript, we first summarize the standard of care of patients with septic shock and current guidelines. We review the physiologic role of vasopressin and its role in septic shock management. We then review the most up-to-date evidence on the potential role of V1a receptor agonists such as Selepressin, in septic shock. Exciting new trials are being completed in order to elucidate the role of V1a receptor agonists as potential first-line vasopressor alternatives in the therapy of circulatory shock in septic patients.
感染性休克仍然是危重症患者发病和死亡的主要原因之一。尽管采取了早期目标导向治疗并使用了儿茶酚胺能药物，但仍有高达30%的患者死于该病。在本手稿中，我们首先总结了感染性休克患者的治疗标准和当前指南。我们回顾了血管加压素的生理作用及其在感染性休克管理中的作用。然后，我们回顾了关于V1a受体激动剂（如司来吉兰）在感染性休克中潜在作用的最新证据。令人兴奋的新试验正在完成，以阐明V1a受体激动剂作为脓毒症患者循环性休克治疗中潜在一线血管升压药替代品的作用。
Zotero 插件